Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca expands jobs cuts

Executive Summary

An additional 4,600 positions are being eliminated, AstraZeneca CEO David Brennan says July 26. The company is expanding on an efficiency initiative involving elimination of 3,000 manufacturing jobs begun in March (1"The Pink Sheet" Feb. 5, 2007, p. 15). Cuts to R&D will result from the conclusion of projects in disease areas that AstraZeneca is no longer pursuing and the "creation of a single data management center to drive significant efficiencies by streamlining the way we manage data," Brennan says. Additional reductions come from manufacturing, European sales, and marketing and business support functions...
Advertisement

Related Content

AstraZeneca’s overseas job cuts
AstraZeneca Cuts 3,000 Manufacturing Jobs, Pares Down Therapeutic Areas
AstraZeneca Cuts 3,000 Manufacturing Jobs, Pares Down Therapeutic Areas
Advertisement
UsernamePublicRestriction

Register

PS048612

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel